KRAS G12D clinical trials at UCSD

1 research study open to eligible people

BBO-11818 in Adult Subjects With KRAS Mutant Cancer
open to eligible people ages 18 years and up
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
San Diego 5391811, California 5332921 and other locations

Last updated: September 12, 2025